Please assess the completion status of the following clinical trial:

Trial Title: A Study of the Efficacy and Safety of Trastuzumab Emtansine (Trastuzumab-MCC-DM1) vs. Trastuzumab (Herceptin®) and Docetaxel (Taxotere®) in Patients With Metastatic HER2-positive Breast Cancer Who Have Not Received Prior Chemotherapy for Metastatic Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically or cytologically confirmed adenocarcinoma of the breast with locally advanced or metastatic disease, and a candidate for chemotherapy.~* Human epidermal growth factor receptor 2 (HER2)-positive.~* No prior chemotherapy for their metastatic breast cancer (MBC).~* Measurable disease.~* Age ≥ 18 years.~* For women of childbearing potential and men with partners of childbearing potential, agreement to use a highly effective, non-hormonal form of contraception or 2 effective forms of non-hormonal contraception by the patient and/or partner. Contraception use must continue for the duration of study treatment and for at least 6 months after the last dose of study treatment. Male patients whose partners are pregnant should use condoms for the duration of the study.~Exclusion Criteria:~* History of any chemotherapy for MBC.~* An interval of \< 6 months from the completion of cytotoxic chemotherapy in the neo-adjuvant or adjuvant setting until the time of metastatic diagnosis.~* Trastuzumab ≤ 21 days prior to randomization.~* Hormone therapy \< 7 days prior to randomization.~* Current peripheral neuropathy of Grade ≥ 3.~* History of other malignancy within the last 5 years, except for appropriately treated carcinoma in situ of the cervix, non-melanoma skin carcinoma, Stage I uterine cancer, or other cancers with a similar outcome as those previously mentioned.~* Previous radiotherapy for the treatment of unresectable, locally advanced or metastatic breast cancer is not allowed if more than 25% of marrow-bearing bone has been irradiated or the last fraction of radiotherapy has been administered within approximately 3 weeks prior to randomization.~* Brain metastases that are untreated, symptomatic, or require therapy to control symptoms or any radiation, surgery, or other therapy to control symptoms from brain metastases within 2 months prior to randomization.~* History of exposure to the following cumulative doses of anthracyclines: Doxorubicin or liposomal doxorubicin \> 500 mg/m\^2; epirubicin \> 900 mg/m\^2; mitoxantrone \> 120mg/m\^2 and idarubicin \> 90 mg/m\^2.~* Current unstable angina.~* History of symptomatic congestive heart failure, or ventricular arrhythmia requiring treatment.~* History of myocardial infarction within 6 months prior to randomization.~* Left ventricular ejection fraction (LVEF) below 50% within approximately 28 days prior to randomization.~* History of decreased LVEF or symptomatic congestive heart failure (CHF) with previous adjuvant trastuzumab treatment.~* Cardiac troponin I ≥ 0.2 ng/mL within 28 days of randomization.~* Severe dyspnea at rest because of complications of advanced malignancy or requiring current continuous oxygen therapy.~* Current severe, uncontrolled systemic disease (eg, clinically significant cardiovascular, pulmonary, or metabolic disease; wound healing disorders; ulcers; or bone fractures).~* Major surgical procedure or significant traumatic injury within approximately 28 days prior to randomization or anticipation of the need for major surgery during the course of study treatment.~* Current pregnancy or lactation.~* History of receiving any investigational treatment within approximately 28 days prior to randomization.~* Current known infection with human immunodeficiency virus (HIV), active hepatitis B and/or hepatitis C virus.~* History of intolerance (including Grade 3-4 infusion reaction) or hypersensitivity to trastuzumab, murine proteins, or docetaxel.~* Known hypersensitivity to any of the study drugs, including the excipients, or any drugs formulated in polysorbate 80.~* Assessed by the investigator to be unable or unwilling to comply with the requirements of the protocol.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Trastuzumab emtansine (Type: EXPERIMENTAL): Patients received trastuzumab emtansine 3.6 mg/kg intravenously (IV) administered over 30-90 minutes every 3 weeks on Day 1 of each 21-day cycle.
- Trastuzumab + docetaxel (Type: ACTIVE_COMPARATOR): Patients received a loading dose of trastuzumab 8 mg/kg IV + docetaxel 75 or 100 mg/m\^2 IV on Day 1 of Cycle 1 followed by trastuzumab 6 mg/kg IV + docetaxel 75 or 100 mg/m\^2 IV on Day 1 of all subsequent 21-day cycles.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete